Alnylam announces promotion of pushkal garg to chief research and development officer

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rna interference (rnai) therapeutics company, today announced that pushkal garg, m.d., has been appointed executive vice president, chief research and development officer to oversee an integrated r&d organization. building on the launch of amvuttra® in transthyretin amyloidosis with cardiomyopathy (attr-cm), alnylam is entering a new phase of growth, and a combined r&d organization will accelera.
ALNY Ratings Summary
ALNY Quant Ranking